11-01-2022 | SGLT2 inhibitors | News
People with type 1 diabetes who take GLP-1 receptor agonists or SGLT2 inhibitors in clinical practice have outcomes that are mostly – but not all – in line with those in controlled trials, say researchers.
10-10-2022 | Semaglutide | News
The substantial weight loss achieved with weekly semaglutide 2.4 mg is maintained if people continue to take the medication for 2 years, show the STEP 5 results.
08-09-2022 | Older adults | News
Lifestyle intervention proves “highly successful” in adults with diabetes aged 65 to 85 years, improving both metabolic and functional health, report researchers.
Get the latest results and insights from the researchers.
01-17-2023 | Lifestyle interventions | News
01-16-2023 | Diet | News
01-09-2023 | Semaglutide | News
12-19-2022 | Early onset | News
Primary findings, 2-year outcomes and translating this landmark trial into practice
12-16-2022 | Diet | News
12-13-2022 | Diet | News
12-01-2022 | Semaglutide | News
11-24-2022 | Ethnic groups | News
11-02-2022 | Semaglutide | News
10-28-2022 | Physical activity | News
10-20-2022 | Gestational diabetes | News
Get the latest developments in diabetes delivered straight to your inbox